Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) EBIT Margin (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed EBIT Margin for 1 consecutive years, with 43981.65% as the latest value for Q2 2025.

  • On a quarterly basis, EBIT Margin changed N/A to 43981.65% in Q2 2025 year-over-year; TTM through Dec 2025 was 23.83%, a N/A change, with the full-year FY2025 number at 7.21%, changed N/A from a year prior.
  • EBIT Margin was 43981.65% for Q2 2025 at Neuphoria Therapeutics, up from 79.85% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 43981.65% in Q2 2025 to a low of 79.85% in Q1 2025.